Advanced Technology Program ATP Home Page NIST Home Page

Project Brief


High-Throughput Platform for Targeted Nanoparticle Engineering


Develop a high-throughput combinatorial platform for nanoparticle engineering that enables the fabrication, screening and optimization of targeted polymeric nanoparticles for drug delivery.

Sponsor: BIND Biosciences, Inc.

101 Binney Street
Cambridge, MA 02142
  • Project Performance Period: 12/1/2007 - 11/30/2010
  • Total project (est.): $3,851,916.00
  • Requested ATP funds: $2,000,000.00

Nanotechnology is expected to have a revolutionary impact on the U.S. healthcare system and economy. One important medical application of nanotechnology is the development of targeted nanoparticles capable of selectively targeting diseased cells and tissues for drug delivery. Nanoparticle-based drug delivery technologies may, in part, overcome the toxicity, efficacy and delivery challenges that are commonly encountered in the pharmaceutical and biotechnology industries. BIND has proposed developing a high-throughput combinatorial platform for nanoparticle engineering that enables the fabrication, screening and optimization of targeted polymeric nanoparticles for desired therapeutic applications. While BIND's focus is therapeutic applications, the platform may be used by others to develop applications in the diagnostic, veterinary and material science areas. As a proof-of-concept, BIND will encapsulate three representative therapeutic agents in targeted nanoparticles and test their efficacy on models of metastatic prostate cancer, laying the groundwork for future clinical trials. BIND is developing a novel class of targeted nanoparticle therapeutics that will enable the intracellular delivery of large payloads of therapeutic drugs, including small molecules, peptides, proteins and nucleic acids. The project is high-risk because of the difficulty in producing nanoparticle drug carriers that can both target the organ or cells of interest and evade the body's immune system. If successful, BIND's technology promises to have widespread impact in multiple therapeutic areas, including oncology, cardiovascular, inflammation and metabolic diseases.

For project information:
Glenn Batchelder, (617) 491-3400
glennbatchelder@bindbio.com

ATP Project Manager
Mrunal Chapekar, (301) 975-6846
mrunal.chapekar@nist.gov


ATP website comments: webmaster-atp@nist.gov
Privacy Statement / Security Notice NIST Disclaimer NIST Information Quality Standards
NIST is an agency of the U.S. Commerce Department